Literature DB >> 25200288

Monepantel: the most studied new anthelmintic drug of recent years.

L Lecová1, L Stuchlíková1, L Prchal1, L Skálová1.   

Abstract

Monepantel (MOP), a new anthelmintic drug from a group of amino-acetonitrile derivatives, has been intensively studied during last years. Many authors examined this new drug from different perspectives, e.g. efficacy against different species and stages of parasites, mode of action, metabolism, pharmacokinetics, toxicity, resistance, ecotoxicity, etc. MOP is an anthelmintic for livestock (currently only sheep and goats), with molecular mode of action which is different to all other anthelmintics. MOP has a broad-spectrum of activity against gastrointestinal nematodes of sheep, including adults and L4 larvae of the most important species. The key feature of MOP is its full effectiveness against strains of nematodes resistant to benzimidazoles, levamisole, macrocyclic lactones and closantel. After oral administration, MOP is quickly absorbed into the bloodstream and quickly metabolized to MOP sulfone that has a similar efficacy as the parent molecule. Several other MOP metabolites formed in ovine hepatocytes were described. MOP and its metabolites are considered to be non-toxic to environment and its components, such as soil microflora, aquatic organisms, dung organisms, vegetation, etc. The aim of the presented review was not to collect all reported data but to bring an overview of various approaches in the study of MOP and to evaluate their principal results.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25200288     DOI: 10.1017/S0031182014001401

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  8 in total

1.  Update on prevention and treatment of intestinal helminth infections.

Authors:  Paul Blair; David Diemert
Journal:  Curr Infect Dis Rep       Date:  2015-03       Impact factor: 3.725

2.  Effectiveness of Anthelmintic Treatments in Small Ruminants in Germany.

Authors:  Katja Voigt; Maximilian Geiger; Miriam Carmen Jäger; Gabriela Knubben-Schweizer; Christina Strube; Yury Zablotski
Journal:  Animals (Basel)       Date:  2022-06-09       Impact factor: 3.231

3.  A preliminary assessment of oral monepantel's tolerability and pharmacokinetics in individuals with treatment-refractory solid tumors.

Authors:  Anna Mislang; Richard Mollard; Gonzalo Tapia Rico; W Douglas Fairlie; Erinna F Lee; Tiffany J Harris; Roger Aston; Michael P Brown
Journal:  Cancer Chemother Pharmacol       Date:  2020-09-22       Impact factor: 3.333

4.  A BRIEF REVIEW ON THE MODE OF ACTION OF ANTINEMATODAL DRUGS.

Authors:  Melanie Abongwa; Richard J Martin; Alan P Robertson
Journal:  Acta Vet (Beogr)       Date:  2017-06-26       Impact factor: 0.800

5.  Monepantel antitumor activity is mediated through inhibition of major cell cycle and tumor growth signaling pathways.

Authors:  Farnaz Bahrami; Ahmed H Mekkawy; Samina Badar; David L Morris; Mohammad H Pourgholami
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

6.  Diisopropylphenyl-imidazole (DII): A new compound that exerts anthelmintic activity through novel molecular mechanisms.

Authors:  María Gabriela Blanco; María Soledad Vela Gurovic; Gustavo Fabián Silbestri; Andrés Garelli; Sebastián Giunti; Diego Rayes; María José De Rosa
Journal:  PLoS Negl Trop Dis       Date:  2018-12-17

7.  Most common inappropriate drug usage factors in anthelmintic treatment on sheep farms in Latvia.

Authors:  Līga Kovaļčuka; Dace Keidāne; Alīna Kļaviņa; Marta Barbara Grasberga; Armands Vekšins
Journal:  Vet World       Date:  2022-02-04

8.  Increased expression of ATP binding cassette transporter genes following exposure of Haemonchus contortus larvae to a high concentration of monepantel in vitro.

Authors:  Ali Raza; Neil H Bagnall; Abdul Jabbar; Steven R Kopp; Andrew C Kotze
Journal:  Parasit Vectors       Date:  2016-09-29       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.